Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations
PaperCitations, authors & open-access status
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 290 citations, 2022 year and hybrid oa status.
290
Citations
2022
Year
hybrid
OA Status